E-LIB Suche - Ergebnisse für: Marlton, F.

1

From total scattering to total understanding: structure–fun..:

Mullens, B. ; Marlton, F. ; Saura-Múzquiz, M..
Acta Crystallographica Section A Foundations and Advances. 79 (2023) a2 - p. C331-C331 , 2023

Link: https://doi.org/10.1107/..

2

A Structural Study of 0.06LiNbO3-0.94K0.5Na0.5NbO3 from Neu..:

Kong, J. ; Liu, J. ; Marlton, F...
Crystals. 11 (2021) 4 - p. 395 , 2021

Link: https://doi.org/10.3390/..

3

Synergistic hydration distortion mechanism in 6H-Ba4Ta2O9·½..:

Ling, C. D. ; Marlton, F. P. ; Brown, A. J....
Acta Crystallographica Section A Foundations and Advances. 79 (2023) a2 - p. C129-C129 , 2023

Link: https://doi.org/10.1107/..

4

A Structural Study of 0.06LiNbO3-0.94K0.5Na0.5NbO3 from Neu..:

J. Kong ; J. Liu ; F. Marlton..
Hybrid and Composite Crystalline Materials. , 2021

Link: https://doi.org/10.3390/..

5

A Structural Study of 0.06LiNbO 3 -0.94K 0.5 Na 0.5 NbO 3 f..:

J. Kong ; J. Liu ; F. Marlton..
https://www.mdpi.com/2073-4352/11/4/395. , 2021

Link: https://doi.org/10.3390/..

6

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclona..:

Yuen, Sam ; Phillips, Tycel J. ; Bannerji, Rajat...
American Journal of Hematology. 99 (2024) 7 - p. 1281-1289 , 2024

Link: https://doi.org/10.1002/..

7

Venetoclax-rituximab is active in patients with BTKi-expose..:

Lew, Thomas E. ; Bennett, Rory ; Lin, Victor S....
Blood Advances. 8 (2024) 6 - p. 1439-1443 , 2024

Link: https://doi.org/10.1182/..

8

Chronic lymphocytic leukaemia Australasian consensus practi..:

Anderson, Mary A. ; Bennett, Rory ; Badoux, Xavier...
Internal Medicine Journal. 53 (2023) 9 - p. 1678-1691 , 2023

Link: https://doi.org/10.1111/..

9

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and vene..:

Lasater, Elisabeth A. ; Amin, Dhara N. ; Bannerji, Rajat...
American Journal of Hematology. 98 (2023) 3 - p. 449-463 , 2023

Link: https://doi.org/10.1002/..

10

POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS..:

Bannerji, R. ; Yuen, S. ; Phillips, T....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

Correction: First-in-human phase 1 study of the BTK inhibit..:

Byrd, John C. ; Smith, Stephen ; Wagner-Johnston, Nina...
Oncotarget. 10 (2019) 38 - p. 3827-3830 , 2019

Link: https://doi.org/10.18632..

12

AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT R..:

Kim, W.S. ; Assouline, S. ; Bartlett, N.L....
Hematological Oncology. 37 (2019) S2 - p. 567-568 , 2019

Link: https://doi.org/10.1002/..

13

First-in-human phase 1 study of the BTK inhibitor GDC-0853 ..:

Byrd, John C. ; Smith, Stephen ; Wagner-Johnston, Nina...
Oncotarget. 9 (2018) 16 - p. 13023-13035 , 2018

Link: https://doi.org/10.18632..

14

BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRA..:

Trotman, J. ; Opat, S. ; Marlton, P....
Hematological Oncology. 35 (2017) S2 - p. 70-71 , 2017

Link: https://doi.org/10.1002/..

15

HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 ..:

Seymour, J.F. ; Opat, S. ; Cull, G....
Hematological Oncology. 35 (2017) S2 - p. 234-235 , 2017

Link: https://doi.org/10.1002/..